What Causes Psychosis Underlying Biological Environmental Triggers

Substance-Induced and Medical Causes of Psychosis

Pharmacodynamic Effects and Withdrawal Patterns in Substance-Induced Psychosis

Recreational Substances

• Amphetamines (e.g., methamphetamine, MDMA)

  Mechanism: Amphetamines release presynaptic DA and norepinephrine (NE) via reverse transport through the dopamine transporter (DAT), while also inhibiting monoamine oxidase (MAO). This hyperstimulates mesolimbic and mesocortical pathways, inducing paranoia, hallucinations, and delusions.

  Withdrawal psychosis occurs in ~10–30% of chronic users, typically 24–72 hours post-discontinuation, characterized by fatigue, depression, and paranoid ideation. Prolonged use may lead to permanent DA transporter downregulation, increasing vulnerability to schizophrenia-like symptoms.

• Cannabis (Δ9-tetrahydrocannabinol, THC)

  Mechanism: THC binds to cannabinoid receptor 1 (CB1), indirectly increasing DA release in the ventral striatum while suppressing GABAergic interneurons. High-potency strains (e.g., skunk) elevate psychosis risk, particularly in adolescents with genetic predispositions (e.g., COMT Val158Met polymorphism).

  Acute psychosis resolves within days to weeks, but persistent cannabis use disorder (CUD) may precipitate "cannabis-induced psychotic disorder" with symptoms indistinguishable from schizophrenia. Withdrawal (days 1–2 post-cessation) includes insomnia, irritability, and mild hallucinations, though frank psychosis is rare.

• Ketamine and Phencyclidine (PCP)

  Mechanism: NMDA receptor antagonism disrupts glutamatergic transmission, leading to dissociative symptoms and psychosis. Ketamine’s rapid onset (minutes) and short half-life (2–4 hours) contrast with PCP’s longer duration (24–72 hours), but both induce hallucinations, thought disorder, and perceptual distortions.

  Withdrawal psychosis is uncommon but may occur with chronic PCP use, presenting as agitation, paranoia, and tactile hallucinations (e.g., "cocaine bugs"). Ketamine’s neuroprotective properties at sub-anesthetic doses (e.g., in depression trials) complicate its risk-benefit profile.

• Lysergic Acid Diethylamide (LSD) and Psilocybin

  Mechanism: 5-HT2A receptor agonism alters sensory gating and induces "ego dissolution," with cross-talk to DA systems enhancing psychotic symptoms. Tolerance develops rapidly (days), but "flashbacks" (HPPD) may persist for months.

  Acute psychosis is dose-dependent, resolving within hours to days. Chronic use is rare due to rapid tolerance, but individuals with latent schizophrenia may experience unmasking of symptoms.

Prescription and Medication-Induced Psychosis

• Anticholinergics (e.g., benztropine, diphenhydramine)

  Mechanism: Muscarinic ACh receptor blockade increases cortical ACh-DA imbalance, lowering the seizure threshold and promoting psychosis. Risk is dose-dependent and higher in elderly patients.

  Symptoms include confusion, hallucinations, and delusions, resolving within days of discontinuation. Chronic use may lead to irreversible cognitive decline.

• Corticosteroids (e.g., prednisone, dexamethasone)

  Mechanism: Glucocorticoids elevate DA turnover in the striatum and reduce hippocampal neurogenesis, while also inducing hypermetabolism and oxidative stress. Psychosis risk increases with doses >40 mg/day or prolonged use (>3 months).

  Onset is gradual (weeks to months), with symptoms including mania, paranoia, and thought disorder. Tapered discontinuation often resolves symptoms, but some cases progress to steroid-resistant psychosis.

• Interferon-α (IFN-α) and Immunomodulators

  Mechanism: IFN-α stimulates proinflammatory cytokines (e.g., IL-6, TNF-α), which disrupt DA metabolism and blood-brain barrier integrity. Up to 30% of patients develop depression or psychosis within 3–6 months of treatment.

  Psychosis typically resolves with dose reduction or discontinuation, but some cases require antipsychotic augmentation. Underlying autoimmune conditions (e.g., hepatitis C) may confer additional risk.

• Anabolic Steroids (e.g., testosterone, nandrolone)

  Mechanism: Androgen receptors modulate DA and 5-HT systems, with high doses (>10x physiological levels) inducing steroid psychosis via glutamate excitotoxicity and oxidative stress. Risk is higher in polydrug users (e.g., amphetamines).

  Symptoms include paranoia, aggression, and visual hallucinations, emerging within weeks of initiation. Withdrawal (3–6 months post-discontinuation) may exacerbate psychosis due to hormonal rebound.

Medical Conditions Precipitating Psychosis: Pathophysiological Links and Treatment Implications

Neurological Disorders

• Temporal Lobe Epilepsy (TLE)

  Pathophysiology: Interictal spikes in the hippocampus and amygdala disrupt mesial temporal lobe (MTL) circuitry, leading to misattribution of internal states (e.g., déjà vu, forced thoughts) and paranoid ideation. Kindling effects from repeated seizures may permanently alter psychotic vulnerability.

  Psychosis occurs in ~5–10% of TLE patients, often with complex partial seizures. Treatment involves antiepileptic drugs (AEDs) with low psychosis risk (e.g., levetiracetam) and atypical antipsychotics (e.g., quetiapine) for refractory cases.

• Multiple Sclerosis (MS)

  Pathophysiology: Demyelination in white matter tracts (e.g., corpus callosum, frontal lobes) disrupts top-down cognitive control, while chronic inflammation (e.g., IL-17, TNF-α) alters DA and glutamate signaling. Psychosis risk is 2–5x higher than the general population.

  Symptoms include delusions of grandeur or persecution, often linked to lesion load in the DMN. Treatment includes disease-modifying therapies (e.g., natalizumab) and low-dose antipsychotics (e.g., aripiprazole).

• Traumatic Brain Injury (
  

  

  Developmental and Cognitive Contributors to Psychosis

  Early-life cognitive deficits and atypical neurodevelopmental trajectories significantly elevate psychosis risk by disrupting neural plasticity, information processing, and adaptive functioning. These deficits—ranging from subtle working memory impairments to severe executive dysfunction—often emerge in childhood or adolescence, interacting with genetic and environmental stressors to precipitate psychotic symptoms. Neuroimaging studies reveal structural and functional abnormalities in prefrontal, temporal, and parietal cortices, particularly during critical periods of synaptic pruning and myelination. Understanding these trajectories is essential for identifying high-risk populations and implementing early interventions that may mitigate symptom onset.
  

  Neurocognitive Deficits and Neuroimaging Correlates

  Cognitive impairments in psychosis are not uniform but follow a hierarchical pattern, with working memory deficits and executive dysfunction (e.g., set-shifting, inhibition) serving as core vulnerabilities. These deficits correlate with:
  
• Prefrontal cortex (PFC) hypoactivation: Observed in tasks requiring cognitive control, reflecting disrupted top-down regulation of sensory and emotional processing.
• Temporal lobe abnormalities: Reduced gray matter volume in the hippocampus and superior temporal gyrus, linked to auditory hallucinations and thought disorder.
• White matter integrity: Fractional anisotropy (FA) reductions in the corpus callosum and uncinate fasciculus, impairing interhemispheric and limbic communication.

Key findings from neuroimaging studies:


• Structural MRI: Adolescents at clinical high risk (CHR) for psychosis exhibit accelerated cortical thinning in frontal and temporal regions compared to controls (Wood et al., 2015).
• Functional MRI (fMRI): During working memory tasks, CHR individuals show hyperactivation in the default mode network (DMN), suggesting inefficient task-related suppression (Anticevic et al., 2015).
• Diffusion tensor imaging (DTI): Disrupted connectivity in the cingulum bundle correlates with severity of negative symptoms (Karlsgodt et al., 2008).

These deficits are not merely secondary to psychosis but represent endophenotypes—heritable traits that precede symptom onset and may reflect early neurodevelopmental disruptions.


Developmental Trajectory of Psychosis Risk Factors

Key milestones in psychosis vulnerability from infancy to adolescence:

- 0–2 years:


Delayed motor milestones (e.g., sitting, walking) or fine motor clumsiness, associated with later executive dysfunction (Jones et al., 1994).

Reduced social engagement (e.g., limited eye contact, atypical vocalizations), linked to later social withdrawal (Baron-Cohen et al., 1999).

- 3–6 years:


Language delays (e.g., expressive/receptive deficits) or pragmatic language disorders, predictive of thought disorder in adulthood (Cannon et al., 2002).

Increased internalizing behaviors (e.g., anxiety, shyness) in response to sensory overresponsivity.

- 7–12 years:


Poor academic performance (especially in math/logic) due to working memory impairments, often misattributed to ADHD or learning disabilities.

Subclinical psychotic-like experiences (e.g., brief paranoid ideation, magical thinking) in 10–20% of children (Lauber et al., 2011), with persistence increasing risk.

- 13–18 years:


Social withdrawal, reduced peer interactions, and increased solitary activities (e.g., excessive gaming, internet use) as coping mechanisms.

Emergence of subthreshold psychotic symptoms (e.g., mild hallucinations, ideas of reference) in high-risk groups, often triggered by stress or substance use.

This trajectory underscores the sleeper effect of early deficits, where subtle cognitive and social impairments accumulate risk over time, particularly in the context of adolescent brain maturation.


Theoretical Models of Psychosis Development

Three dominant models explain how cognitive and developmental factors contribute to psychosis, each with distinct strengths and limitations:

1. Cognitive Diathesis-Stress Model:
   
2. Core premise: Preexisting cognitive vulnerabilities (e.g., attentional biases, jumping-to-conclusions bias) interact with environmental stressors to trigger psychotic symptoms.
3. Strengths:
4. Explains symptom heterogeneity (e.g., paranoia vs. hallucinations) via domain-specific deficits (e.g., threat processing vs. sensory gating).
5. Aligns with cognitive-behavioral interventions (e.g., CBTp) targeting maladaptive appraisals.
6. Limitations:
7. Underemphasizes biological embedding of cognitive deficits (e.g., genetic/epigenetic contributions).
8. Fails to account for prodromal phases where symptoms emerge without clear stressors.
9. Neurodevelopmental Model:
   
10. Core premise: Psychosis arises from disrupted brain development during critical periods (e.g., prenatal, perinatal, adolescence), leading to structural and functional abnormalities.
11. Strengths:
12. Integrates genetic (e.g., COMT, DRD2 variants) and environmental (e.g., obstetric complications, malnutrition) risk factors.
13. Explains early markers (e.g., motor delays) as indicators of broader neural dysmaturation.
14. Limitations:
15. Overemphasizes linear trajectories; many individuals with early deficits never develop psychosis.
16. Lacks mechanistic clarity on how early disruptions translate to adult symptoms.
17. Interactive Specialization Model:
    
18. Core premise: Psychosis emerges from atypical specialization of neural networks during development, where regions fail to prune or integrate efficiently (e.g., hyperconnected DMN, hypoconnectivity in frontoparietal networks).
19. Strengths:
20. Explains both structural (e.g., gray matter reductions) and functional (e.g., DMN hyperactivity) findings.
21. Accounts for compensatory mechanisms (e.g., recruitment of alternative networks).
22. Limitations:
23. Requires advanced neuroimaging to test, limiting clinical applicability.
24. Difficult to disentangle from other neurodevelopmental disorders (e.g., autism, schizophrenia).
Comparison of models:

Model	Focus	Key Predictions	Clinical Utility
Cognitive Diathesis-Stress	Cognitive biases + stressors	Symptoms emerge with stress exposure	Guides CBTp, psychoeducation
Neurodevelopmental	Early brain disruptions	Lifelong structural/functional abnormalities	Early screening, prenatal interventions
Interactive Specialization	Network dysmaturation	Atypical connectivity patterns	Biomarker research, personalized medicine

Sensory Gating Deficits in Psychosis

Sensory gating—the brain’s ability to filter irrelevant stimuli—is impaired in psychosis, particularly in P50 suppression, a measure of auditory evoked potential habituation. Failure to suppress redundant sensory input (e.g., repetitive sounds) may contribute to hallucinations and delusions by overwhelming cognitive resources.

EEG Patterns and Mechanisms:


• P50 suppression deficit: In healthy individuals, the P50 waveform (a positive deflection ~50 ms post-stimulus) diminishes with paired-click paradigms. In psychosis, this suppression is reduced by 30–50% (Adler et al., 1982), reflecting nicotinic cholinergic dysfunction (linked to CHRNA7 gene variants).
• MMN (Mismatch Negativity) abnormalities: Reduced MMN amplitude to deviant auditory stimuli correlates with auditory hallucinations, suggesting impaired predictive coding (Umbricht et al., 2003).
• Theta-gamma coupling deficits: Disrupted phase-amplitude coupling in these bands during sensory processing may underlie the perceptual salience of internal thoughts (e.g., misattributed hallucinations).

Links to Symptoms:


• Hallucinations: Sensory gating deficits may lead to perceptual overload, where internal speech or thoughts are misattributed to external sources (Frith, 1992).
• Delusions: Impaired filtering of irrelevant information (e.g., coincidental events) may fuel jumping-to-conclusions bias, a hallmark of paranoid ideation (Garety et al., 2005).

Neuroanatomical Correlates:


• Thalamocortical dysrhythmia: Abnormal oscillations in the thalamus and auditory cortex, detectable via MEG, may underlie sensory gating failures (Llinás et al., 1999).
• Prefrontal hypoactivity: Reduced top-down modulation of sensory processing, observable during P50 paradigms (Cullum et al., 1993).

Cognitive Reserve as a Protective Factor Against Psychosis

Cognitive reserve—the brain’s capacity to adapt to damage or inefficiency—modulates psychosis risk by delaying or mitigating symptom expression. Higher reserve (e.g., education, complex occupations) may compensate for neurodevelopmental vulnerabilities through neural efficiency, compensatory recruitment, or

Psychosis emerges as a consequence of a fragile equilibrium between inherent neural vulnerabilities and external provocations, where dopamine dysregulation, structural brain anomalies, and inflammatory processes create a permissive environment for symptom onset. Environmental triggers—ranging from cannabis exposure to chronic stress—exacerbate these predispositions, particularly during critical developmental phases, while medical and substance-induced factors introduce additional layers of complexity. The distinction between primary psychotic disorders and secondary forms, such as those induced by substances or medical conditions, further complicates diagnosis and treatment, necessitating a tailored, multidimensional approach. By integrating biological, psychosocial, and cognitive perspectives, this analysis underscores the necessity of personalized interventions that address both the root causes and the broader contextual factors shaping psychosis. The path forward lies in translational research that bridges laboratory discoveries with clinical practice, ultimately aiming to mitigate risk and improve outcomes for individuals navigating this challenging spectrum of disorders.

FAQ

What specific brain changes or mechanisms cause psychosis in the brain?

Psychosis in the brain is linked to dysfunction in neurotransmitters like dopamine (excess activity) and glutamate (imbalance), as well as structural changes such as altered connectivity in the prefrontal cortex, thalamus, and temporal lobes. Neuroimaging studies also show enlarged ventricles and reduced gray matter in some cases. Genetic factors and early brain development disruptions (e.g., prenatal stress) may contribute to these abnormalities.

What are the most common causes of psychosis in adults?

In adults, psychosis is often caused by severe mental illnesses like schizophrenia or bipolar disorder, though it can also stem from substance use (e.g., amphetamines, cannabis, or hallucinogens), brain injuries, or medical conditions like dementia or lupus. Stress, trauma, and sleep deprivation may trigger psychotic episodes in predisposed individuals. Rarely, infections (e.g., syphilis) or metabolic imbalances can induce psychosis.

What triggers episodes of psychosis in people who experience it?

Psychotic episodes can be triggered by extreme stress (e.g., grief, abuse), substance abuse (especially stimulants or psychedelics), sleep deprivation, or withdrawal from medications like antipsychotics. In some cases, infections (e.g., COVID-19), hormonal changes (e.g., postpartum), or neurological conditions (e.g., epilepsy) may also provoke episodes. Environmental factors and genetic vulnerability interact to determine susceptibility.

What causes psychosis in children or adolescents?

Childhood psychosis is often linked to genetic predisposition (e.g., family history of schizophrenia), early brain development issues, or severe trauma (e.g., abuse, neglect). Medical causes like autoimmune disorders (e.g., pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, or PANDAS) or metabolic conditions may also play a role. Substance use (e.g., cannabis) or sleep disorders can trigger episodes in vulnerable youth.

What causes psychosis during the postpartum period?

Postpartum psychosis is primarily caused by severe hormonal fluctuations (e.g., rapid drops in estrogen and progesterone) after childbirth, which can disrupt neurotransmitter systems like dopamine and serotonin. It’s strongly linked to bipolar disorder or a family history of psychosis, and may be triggered by extreme sleep deprivation, stress, or thyroid imbalances. Without treatment, it can lead to severe symptoms like delusions or hallucinations.

What causes psychosis in people with schizophrenia?

Psychosis in schizophrenia is caused by a combination of genetic factors (e.g., mutations in genes regulating dopamine or glutamate) and brain abnormalities, including altered neural connectivity and dopamine dysregulation (excess in mesolimbic pathways). Environmental triggers like childhood trauma, cannabis use, or urban upbringing may interact with these vulnerabilities to initiate or worsen symptoms. The exact cause remains unclear, but it involves a mix of neurobiological and psychological factors.

• dopamine-dysregulation
• environmental-risk-factors
• genetic predisposition
• neuropsychiatry
• psychosis triggers